Report Detail

Pharma & Healthcare Global Tumor Immunity Therapy Market Research Report 2022

  • RnM4482347
  • |
  • 12 August, 2022
  • |
  • Global
  • |
  • 104 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Description:
Highlights

The global Tumor Immunity Therapy market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.

North American market for Tumor Immunity Therapy is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

Asia-Pacific market for Tumor Immunity Therapy is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.

The global market for Tumor Immunity Therapy in Hospital is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.

The major global companies of Tumor Immunity Therapy include Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc. and IMVAQ Therapeutics, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.

Considering the economic change due to COVID-19, Immune Checkpoint Inhibitor, which accounted for % of the global market of Tumor Immunity Therapy in 2021, is expected to reach US$ million by 2028, growing at a revised CAGR of % from 2022 to 2028.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Tumor Immunity Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Immunity Therapy.

The Tumor Immunity Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Tumor Immunity Therapy market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Tumor Immunity Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Bristol-Myers Squibb

Merck & Co., Inc.

Roche AG

AstraZeneca, Plc

Sanofi S.A.

Dendreon Pharmaceuticals

Novartis

Gilead Sciences Inc.

IMVAQ Therapeutics

Arch Oncology

Juno Therapeutics

Refuge

Lebu Biopharma

Genoimmune

TCR Cure

Product Type Insights

Global markets are presented by Tumor Immunity Therapy type, along with growth forecasts through 2028. Estimates on revenue are based on the price in the supply chain at which the Tumor Immunity Therapy are procured by the companies.

This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).

Tumor Immunity Therapy segment by Type

Immune Checkpoint Inhibitor

Cytokine Immunotherapy

Cancer Vaccine

Car-t Cell Therapy

Others

Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).

This report also outlines the market trends of each segment and consumer behaviors impacting the Tumor Immunity Therapy market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Tumor Immunity Therapy market.

Tumor Immunity Therapy Segment by Application

Hospital

Clinic

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2017-2028.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Tumor Immunity Therapy market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Immunity Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Tumor Immunity Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Tumor Immunity Therapy industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Immunity Therapy.

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Tumor Immunity Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue and gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.


Table of content:

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Market Analysis by Type
    • 1.2.1 Global Tumor Immunity Therapy Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
  • 1.2.2 Immune Checkpoint Inhibitor
  • 1.2.3 Cytokine Immunotherapy
  • 1.2.4 Cancer Vaccine
  • 1.2.5 Car-t Cell Therapy
  • 1.2.6 Others
  • 1.3 Market by Application
  • 1.3.1 Global Tumor Immunity Therapy Market Share by Application: 2017 VS 2021 VS 2028
  • 1.3.2 Hospital
  • 1.3.3 Clinic
  • 1.4 Study Objectives
  • 1.5 Years Considered
  • 2 Global Growth Trends

    • 2.1 Global Tumor Immunity Therapy Market Perspective (2017-2028)
    • 2.2 Tumor Immunity Therapy Growth Trends by Region
    • 2.2.1 Tumor Immunity Therapy Market Size by Region: 2017 VS 2021 VS 2028
  • 2.2.2 Tumor Immunity Therapy Historic Market Size by Region (2017-2022)
  • 2.2.3 Tumor Immunity Therapy Forecasted Market Size by Region (2023-2028)
  • 2.3 Tumor Immunity Therapy Market Dynamics
  • 2.3.1 Tumor Immunity Therapy Industry Trends
  • 2.3.2 Tumor Immunity Therapy Market Drivers
  • 2.3.3 Tumor Immunity Therapy Market Challenges
  • 2.3.4 Tumor Immunity Therapy Market Restraints
  • 3 Competition Landscape by Key Players

    • 3.1 Global Top Tumor Immunity Therapy Players by Revenue
    • 3.1.1 Global Top Tumor Immunity Therapy Players by Revenue (2017-2022)
  • 3.1.2 Global Tumor Immunity Therapy Revenue Market Share by Players (2017-2022)
  • 3.2 Global Tumor Immunity Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.3 Players Covered: Ranking by Tumor Immunity Therapy Revenue
  • 3.4 Global Tumor Immunity Therapy Market Concentration Ratio
  • 3.4.1 Global Tumor Immunity Therapy Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Tumor Immunity Therapy Revenue in 2021
  • 3.5 Tumor Immunity Therapy Key Players Head office and Area Served
  • 3.6 Key Players Tumor Immunity Therapy Product Solution and Service
  • 3.7 Date of Enter into Tumor Immunity Therapy Market
  • 3.8 Mergers & Acquisitions, Expansion Plans
  • 4 Tumor Immunity Therapy Breakdown Data by Type

    • 4.1 Global Tumor Immunity Therapy Historic Market Size by Type (2017-2022)
    • 4.2 Global Tumor Immunity Therapy Forecasted Market Size by Type (2023-2028)

    5 Tumor Immunity Therapy Breakdown Data by Application

    • 5.1 Global Tumor Immunity Therapy Historic Market Size by Application (2017-2022)
    • 5.2 Global Tumor Immunity Therapy Forecasted Market Size by Application (2023-2028)

    6 North America

    • 6.1 North America Tumor Immunity Therapy Market Size (2017-2028)
    • 6.2 North America Tumor Immunity Therapy Market Size by Country (2017-2022)
    • 6.3 North America Tumor Immunity Therapy Market Size by Country (2023-2028)
    • 6.4 United States
    • 6.5 Canada

    7 Europe

    • 7.1 Europe Tumor Immunity Therapy Market Size (2017-2028)
    • 7.2 Europe Tumor Immunity Therapy Market Size by Country (2017-2022)
    • 7.3 Europe Tumor Immunity Therapy Market Size by Country (2023-2028)
    • 7.4 Germany
    • 7.5 France
    • 7.6 U.K.
    • 7.7 Italy
    • 7.8 Russia
    • 7.9 Nordic Countries

    8 Asia-Pacific

    • 8.1 Asia-Pacific Tumor Immunity Therapy Market Size (2017-2028)
    • 8.2 Asia-Pacific Tumor Immunity Therapy Market Size by Country (2017-2022)
    • 8.3 Asia-Pacific Tumor Immunity Therapy Market Size by Country (2023-2028)
    • 8.4 China
    • 8.5 Japan
    • 8.6 South Korea
    • 8.7 Southeast Asia
    • 8.8 India
    • 8.9 Australia

    9 Latin America

    • 9.1 Latin America Tumor Immunity Therapy Market Size (2017-2028)
    • 9.2 Latin America Tumor Immunity Therapy Market Size by Country (2017-2022)
    • 9.3 Latin America Tumor Immunity Therapy Market Size by Country (2023-2028)
    • 9.4 Mexico
    • 9.5 Brazil

    10 Middle East & Africa

    • 10.1 Middle East & Africa Tumor Immunity Therapy Market Size (2017-2028)
    • 10.2 Middle East & Africa Tumor Immunity Therapy Market Size by Country (2017-2022)
    • 10.3 Middle East & Africa Tumor Immunity Therapy Market Size by Country (2023-2028)
    • 10.4 Turkey
    • 10.5 Saudi Arabia
    • 10.6 UAE

    11 Key Players Profiles

    • 11.1 Bristol-Myers Squibb
    • 11.1.1 Bristol-Myers Squibb Company Detail
  • 11.1.2 Bristol-Myers Squibb Business Overview
  • 11.1.3 Bristol-Myers Squibb Tumor Immunity Therapy Introduction
  • 11.1.4 Bristol-Myers Squibb Revenue in Tumor Immunity Therapy Business (2017-2022)
  • 11.1.5 Bristol-Myers Squibb Recent Development
  • 11.2 Merck & Co., Inc.
  • 11.2.1 Merck & Co., Inc. Company Detail
  • 11.2.2 Merck & Co., Inc. Business Overview
  • 11.2.3 Merck & Co., Inc. Tumor Immunity Therapy Introduction
  • 11.2.4 Merck & Co., Inc. Revenue in Tumor Immunity Therapy Business (2017-2022)
  • 11.2.5 Merck & Co., Inc. Recent Development
  • 11.3 Roche AG
  • 11.3.1 Roche AG Company Detail
  • 11.3.2 Roche AG Business Overview
  • 11.3.3 Roche AG Tumor Immunity Therapy Introduction
  • 11.3.4 Roche AG Revenue in Tumor Immunity Therapy Business (2017-2022)
  • 11.3.5 Roche AG Recent Development
  • 11.4 AstraZeneca, Plc
  • 11.4.1 AstraZeneca, Plc Company Detail
  • 11.4.2 AstraZeneca, Plc Business Overview
  • 11.4.3 AstraZeneca, Plc Tumor Immunity Therapy Introduction
  • 11.4.4 AstraZeneca, Plc Revenue in Tumor Immunity Therapy Business (2017-2022)
  • 11.4.5 AstraZeneca, Plc Recent Development
  • 11.5 Sanofi S.A.
  • 11.5.1 Sanofi S.A. Company Detail
  • 11.5.2 Sanofi S.A. Business Overview
  • 11.5.3 Sanofi S.A. Tumor Immunity Therapy Introduction
  • 11.5.4 Sanofi S.A. Revenue in Tumor Immunity Therapy Business (2017-2022)
  • 11.5.5 Sanofi S.A. Recent Development
  • 11.6 Dendreon Pharmaceuticals
  • 11.6.1 Dendreon Pharmaceuticals Company Detail
  • 11.6.2 Dendreon Pharmaceuticals Business Overview
  • 11.6.3 Dendreon Pharmaceuticals Tumor Immunity Therapy Introduction
  • 11.6.4 Dendreon Pharmaceuticals Revenue in Tumor Immunity Therapy Business (2017-2022)
  • 11.6.5 Dendreon Pharmaceuticals Recent Development
  • 11.7 Novartis
  • 11.7.1 Novartis Company Detail
  • 11.7.2 Novartis Business Overview
  • 11.7.3 Novartis Tumor Immunity Therapy Introduction
  • 11.7.4 Novartis Revenue in Tumor Immunity Therapy Business (2017-2022)
  • 11.7.5 Novartis Recent Development
  • 11.8 Gilead Sciences Inc.
  • 11.8.1 Gilead Sciences Inc. Company Detail
  • 11.8.2 Gilead Sciences Inc. Business Overview
  • 11.8.3 Gilead Sciences Inc. Tumor Immunity Therapy Introduction
  • 11.8.4 Gilead Sciences Inc. Revenue in Tumor Immunity Therapy Business (2017-2022)
  • 11.8.5 Gilead Sciences Inc. Recent Development
  • 11.9 IMVAQ Therapeutics
  • 11.9.1 IMVAQ Therapeutics Company Detail
  • 11.9.2 IMVAQ Therapeutics Business Overview
  • 11.9.3 IMVAQ Therapeutics Tumor Immunity Therapy Introduction
  • 11.9.4 IMVAQ Therapeutics Revenue in Tumor Immunity Therapy Business (2017-2022)
  • 11.9.5 IMVAQ Therapeutics Recent Development
  • 11.10 Arch Oncology
  • 11.10.1 Arch Oncology Company Detail
  • 11.10.2 Arch Oncology Business Overview
  • 11.10.3 Arch Oncology Tumor Immunity Therapy Introduction
  • 11.10.4 Arch Oncology Revenue in Tumor Immunity Therapy Business (2017-2022)
  • 11.10.5 Arch Oncology Recent Development
  • 11.11 Juno Therapeutics
  • 11.11.1 Juno Therapeutics Company Detail
  • 11.11.2 Juno Therapeutics Business Overview
  • 11.11.3 Juno Therapeutics Tumor Immunity Therapy Introduction
  • 11.11.4 Juno Therapeutics Revenue in Tumor Immunity Therapy Business (2017-2022)
  • 11.11.5 Juno Therapeutics Recent Development
  • 11.12 Refuge
  • 11.12.1 Refuge Company Detail
  • 11.12.2 Refuge Business Overview
  • 11.12.3 Refuge Tumor Immunity Therapy Introduction
  • 11.12.4 Refuge Revenue in Tumor Immunity Therapy Business (2017-2022)
  • 11.12.5 Refuge Recent Development
  • 11.13 Biopharma Dust
  • 11.13.1 Lepu Biopharma Company Detail
  • 11.13.2 Lepu Biopharma Business Overview
  • 11.13.3 Lepu Biopharma Tumor Immunity Therapy Introduction
  • 11.13.4 Lepu Biopharma Revenue in Tumor Immunity Therapy Business (2017-2022)
  • 11.13.5 Lepu Biopharma Recent Development
  • 11.14 Genoimmune
  • 11.14.1 Genoimmune Company Detail
  • 11.14.2 Genoimmune Business Overview
  • 11.14.3 Genoimmune Tumor Immunity Therapy Introduction
  • 11.14.4 Genoimmune Revenue in Tumor Immunity Therapy Business (2017-2022)
  • 11.14.5 Genoimmune Recent Development
  • 11.15 TCR Cure
  • 11.15.1 TCR Cure Company Detail
  • 11.15.2 TCR Cure Business Overview
  • 11.15.3 TCR Cure Tumor Immunity Therapy Introduction
  • 11.15.4 TCR Cure Revenue in Tumor Immunity Therapy Business (2017-2022)
  • 11.15.5 TCR Cure Recent Development
  • 12 Analyst's Viewpoints/Conclusions

      13 Appendix

      • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
    • 13.1.2 Data Source
    • 13.2 Disclaimer
    • Summary:
      Get latest Market Research Reports on Tumor Immunity Therapy. Industry analysis & Market Report on Tumor Immunity Therapy is a syndicated market report, published as Global Tumor Immunity Therapy Market Research Report 2022. It is complete Research Study and Industry Analysis of Tumor Immunity Therapy market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $2,900.00
      $5,800.00
      2,241.70
      4,483.40
      2,699.90
      5,399.80
      442,801.00
      885,602.00
      244,760.00
      489,520.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report